Arcturus Therapeutics

Company snapshot

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. A

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 55 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Arcturus Therapeutics. Not investment advice.

• Presentation Jun 5, 2026
  Arcturus Therapeutics: Phase 3 Study of ARCT-810 (mRNA Therapeutic) for Ornithine Transcarbamylase Deficiency
• Congress Jun 3, 2026
  THMA Pharmacy Growth

• Peer + 0 momentum

  Atea Pharmaceuticals

  TA overlap score 27.4

• Peer + 0 momentum

  Vir Biotechnology

  TA overlap score 26.8

• Peer + 0 momentum

  WINDTREE THERAPEUTICS INC

  TA overlap score 23

• Peer + 0 momentum

  RedHill Biopharma

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Arcturus Therapeutics.

1. Jun 8, 2026 Clinical update

   ARCT-032-02 — Phase 2

2. Jun 8, 2026 Clinical update

   SARS-CoV-2 mRNA Vaccine ARCT-021 — Phase 2

3. Jun 8, 2026 Clinical update

   ARCT-2303 — Phase 3

4. Jun 8, 2026 Clinical update

   ARCT-165 — Phase 2

5. Jun 5, 2026 Clinical update

   ARCT-2304 — Phase 1

View all clinical trial activity →

• What is Arcturus Therapeutics?

  Arcturus Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker ARCT. Primary therapeutic focus areas include COVID-19, Cystic Fibrosis, Influenza, Human, SARS-CoV-2, Covid19. NovaPharmaNews links 13 clinical program(s), 0 drug profi

• Is Arcturus Therapeutics publicly traded?

  Yes. Arcturus Therapeutics is listed with ticker ARCT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Arcturus Therapeutics develop or market?

  We link 7 drug profile(s) where Arcturus Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arcturus-therapeutics-holdings#company-drugs.

• What are the latest developments for Arcturus Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Arcturus Therapeutics focus on?

  Arcturus Therapeutics focuses on COVID-19, Cystic Fibrosis, Influenza, Human based on our analysis of their pipeline programs and drug development activities.